Cargando…

Measuring Quality of Life Using Patient-Reported Outcomes in Real-World Metastatic Breast Cancer Patients: The Need for a Standardized Approach

SIMPLE SUMMARY: Metastatic breast cancer (MBC) remains incurable despite treatment improvements. The health-related quality of life is a multidimensional entity which covers physical, psychological and social dimensions. It is an important outcome particularly in patients with metastatic disease, as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Clarijs, Marloes E., Thurell, Jacob, Kühn, Friedrich, Uyl-de Groot, Carin A., Hedayati, Elham, Karsten, Maria M., Jager, Agnes, Koppert, Linetta B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8151772/ https://www.ncbi.nlm.nih.gov/pubmed/34065805 http://dx.doi.org/10.3390/cancers13102308

Ejemplares similares

Risk-adjusted benchmarking of long-term overall survival in patients with HER2-positive early-stage Breast cancer: A Swedish retrospective cohort study
por: Thurell, Jacob, et al.
Publicado: (2023)

Quality of life of caregivers of breast cancer patients: a cross-sectional evaluation
por: Clarijs, Marloes E., et al.
Publicado: (2022)

Correction: Quality of life of caregivers of breast cancer patients: a cross-sectional evaluation
por: Clarijs, Marloes E., et al.
Publicado: (2022)

Bilateral prophylactic mastectomy: should we preserve the pectoral fascia? Protocol of a Dutch double blinded, prospective, randomised controlled pilot study with a within-subject design (PROFAS)
por: Clarijs, Marloes E, et al.
Publicado: (2023)

Health-related Quality of Life using the EQ-5D-5L: normative utility scores in a Dutch female population
por: Clarijs, Marloes E., et al.
Publicado: (2022)

Regulatory Approval, Reimbursement, and Clinical Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic Breast Cancer in the Netherlands
por: Luyendijk, Marianne, et al.
Publicado: (2023)

BREAST-Q Breast-Conserving Therapy Module: Normative Data from a Dutch Sample of 9059 Women
por: Oemrawsingh, Arvind, et al.
Publicado: (2022)

Cost-Effectiveness of Abemaciclib in Early Breast Cancer Patients: One Size Fits All or Tailoring to Patients’ Needs?
por: Jongbloed, Elisabeth M, et al.
Publicado: (2023)

Real-world cost-effectiveness of cetuximab in the third-line treatment of metastatic colorectal cancer based on patient chart review in the Netherlands
por: Uyl-de Groot, Carin A., et al.
Publicado: (2018)

Cost-Effectiveness Analysis of MammaPrint(®) to Guide the Use of Endocrine Therapy in Patients with Early-Stage Breast Cancer
por: Luyendijk, Marianne, et al.
Publicado: (2023)

Quality of Life and Complications after Nipple- versus Skin-Sparing Mastectomy followed by Immediate Breast Reconstruction: A Systematic Review and Meta-Analysis
por: Clarijs, Marloes E., et al.
Publicado: (2023)

Hospital-based or home-based administration of oncology drugs? A micro-costing study comparing healthcare and societal costs of hospital-based and home-based subcutaneous administration of trastuzumab
por: Franken, Margreet, et al.
Publicado: (2020)

A preliminary prediction model for potentially guiding patient choices between breast conserving surgery and mastectomy in early breast cancer patients; a Dutch experience
por: Vos, Elvira, et al.
Publicado: (2017)

Expanded Access as a source of real‐world data: An overview of FDA and EMA approvals
por: Polak, Tobias B., et al.
Publicado: (2020)

Changes in survival in de novo metastatic cancer in an era of new medicines
por: Luyendijk, Marianne, et al.
Publicado: (2023)

Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age
por: Drooger, Jan C., et al.
Publicado: (2015)

Analysis of patient reported outcomes included in the registrational clinical trials of nivolumab for advanced non-small cell lung cancer
por: Zaim, Remziye, et al.
Publicado: (2022)

Omitting re-excision for focally positive margins after breast-conserving surgery does not impair disease-free and overall survival
por: Vos, Elvira L., et al.
Publicado: (2017)

Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer
por: Zaim, Remziye, et al.
Publicado: (2023)

Real-world data from expanded access programmes in health technology assessments: a review of NICE technology appraisals
por: Polak, Tobias B, et al.
Publicado: (2022)

Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial
por: Braal, C. Louwrens, et al.
Publicado: (2022)

Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands
por: Xander, Nicolas S. H., et al.
Publicado: (2023)

Use of data-mining to support real-world cost analyses: An example using HER2-positive breast cancer in Iran
por: Ansaripour, Amir, et al.
Publicado: (2018)

Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments
por: De Groot, S., et al.
Publicado: (2017)

Health-related quality of life of multiple sclerosis patients: a European multi-country study
por: Visser, Laurenske A., et al.
Publicado: (2021)

A descriptive systematic review of the relationship between personality traits and quality of life of women with non-metastatic breast cancer
por: Wintraecken, Veerle Marieke, et al.
Publicado: (2022)

Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
por: Ansaripour, Amir, et al.
Publicado: (2017)

Economic evaluations of big data analytics for clinical decision-making: a scoping review
por: Bakker, Lytske, et al.
Publicado: (2020)

How can we discover the most valuable types of big data and artificial intelligence-based solutions? A methodology for the efficient development of the underlying analytics that improve care
por: Bakker, Lytske, et al.
Publicado: (2021)

Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment
por: Zaim, Remziye, et al.
Publicado: (2023)

Lenalidomide as maintenance treatment for patients with multiple myeloma after autologous stem cell transplantation: A pharmaco‐economic assessment
por: Uyl‐de Groot, Carin A., et al.
Publicado: (2020)

Fair Pricing of Innovative Medicines: An EHA Position Paper
por: Hagenbeek, Anton, et al.
Publicado: (2020)

Reliability and Efficiency of the CAPRI-3 Metastatic Prostate Cancer Registry Driven by Artificial Intelligence
por: Bosch, Dianne, et al.
Publicado: (2023)

Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma
por: de Groot, S., et al.
Publicado: (2017)

A Practical Guide for Using Registry Data to Inform Decisions About the Cost Effectiveness of New Cancer Drugs: Lessons Learned from the PHAROS Registry
por: Blommestein, Hedwig M., et al.
Publicado: (2015)

Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks
por: van der Gronde, Toon, et al.
Publicado: (2017)

Unequal Access to Newly Registered Cancer Drugs Leads to Potential Loss of Life-Years in Europe
por: Uyl-de Groot, Carin A., et al.
Publicado: (2020)

Proof-of-concept study linking ex vivo sensitivity testing to neoadjuvant anthracycline-based chemotherapy response in breast cancer patients
por: Ladan, Marjolijn M., et al.
Publicado: (2023)

Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations
por: Holleman, Marscha S., et al.
Publicado: (2019)

Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study
por: Doebar, Shusma C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_hklb19qutjfqkmlbd5hgr5kqgb